Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

109.73 +0.33 (+0.30%)
Official Closing Price Updated: 7:00 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
2 Incredibly Cheap Big Pharma Stocks to Buy Now
There's doubtlessly some coming uncertainty for both, but the prices are right. 
Via The Motley Fool
A Closer Look at Merck & Co's Options Market Dynamics
Via Benzinga
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
Goldman Sachs identifies 18 stocks for potential earnings upside and advises options-based strategies in a volatile market. 10% upside for S&P 500. 
Via Benzinga
Topics Stocks
Exposures US Equities
Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer
On Sunday, The Guardian issued an article that spoke of a UK study that could transform how cancer is treated. The large-scale clinical project assessed how personalized cancer therapies could... 
Via Benzinga
Demystifying Merck & Co: Insights From 8 Analyst Reviews
Via Benzinga
Exploring The Competitive Space: Merck &amp; Co Versus Industry Peers In Pharmaceuticals
Via Benzinga
Is Merck Stock a Buy?
There is mounting pressure on the company's most prized franchise. 
Via The Motley Fool
NYSE:MRK stands out as a stock that provides good value for the fundamentals it showcases.
When you look at MERCK & CO. INC. (NYSE:MRK), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock'
Target (TGT) stock recommended by Jim Cramer at current price with plans to buy more. Merck (MRK) and Unity Software (U) also discussed. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Merck's Mumps Vaccine Controversy: Class-Action Lawsuit Alleges Anticompetitive Behavior, Court Shields From Liability
Merck faces a class-action lawsuit over alleged misrepresentation of its mumps vaccine potency, claiming anticompetitive practices to maintain market dominance. Despite ethical concerns, the court... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Merck Touts Phase 3 Success For $20B Cancer Drug Keytruda In Untreated Head And Neck Cancer Patients
Merck's Keytruda (pembrolizumab) met primary endpoint of event-free survival (EFS) in Phase 3 trial for newly diagnosed head and neck cancer patients. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
This Is What Whales Are Betting On Merck & Co
Via Benzinga
Merck & Co Unusual Options Activity For September 23
Via Benzinga
Exploring NYSE:MRK's dividend characteristics.
Why the dividend investor may take a look at MERCK & CO. INC. (NYSE:MRK). 
Via Chartmill
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
The investment bank analysts who follow these stocks think they can soar even further, with some caveats. 
Via The Motley Fool
Is It Time to Buy September's Worst-Performing Dow Jones Stocks?
They may technically be blue chips, but that doesn't necessarily make them your best bets at their discounted prices. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
Thermo Fisher's Greenville facility, one of the largest in the U.S., has faced repeated FDA regulatory violations. Key concerns include contamination prevention and inadequate equipment sterilization... 
Via Benzinga
Exposures Product Safety
Could Summit Therapeutics Become the Next Merck?
Recent developments are forcing comparisons between these two drugmakers. 
Via The Motley Fool
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
The Covid Era Tech Promises To Reinvent Cancer Treatment
Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning to oncology for its next growth story. 
Via Benzinga
Exposures COVID-19
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit 
Via News Direct
2 High-Potential Growth Stocks You Shouldn't Overlook
These two growth stocks have plenty of room to run. 
Via The Motley Fool
Evaxion Biotech Partners With Merck To Expand Vaccine Development
Evaxion Biotech enters an expanded collaboration with Merck, granting an option to license preclinical vaccine candidates. The deal includes $3.2 million upfront and potential earnings up to $592... 
Via Benzinga
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks and benefits for those with varying PD-L1 levels, including low expressers. 
Via Benzinga
Exposures Product Safety
Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years
Eli Lilly presents promising long-term data showing Ebglyss' efficacy in treating moderate-to-severe atopic dermatitis, with over 80% of patients maintaining clear skin for up to three years. FDA and... 
Via Benzinga
Exposures Product Safety
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
Merck's Phase 3 KEYFORM-007 study on the combination of favezelimab and pembrolizumab in MSS mCRC patients did not improve overall survival compared to standard treatments, though safety remained... 
Via Benzinga
Pfizer Advances On Its Cancer Journey
On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024... 
Via Benzinga
Is It Too Late to Buy ServiceNow Stock?
The stock is up nearly 60% since the beginning of the year. 
Via The Motley Fool
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.